Nurix Therapeutics, Inc.
NRIX
$15.60
-$0.13-0.83%
NASDAQ
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.60% | -76.53% | 2.43% | -35.73% | -39.55% |
| Total Depreciation and Amortization | 34.23% | 20.60% | 24.59% | 6.17% | 27.41% |
| Total Amortization of Deferred Charges | -53.85% | -- | -- | -- | -7.14% |
| Total Other Non-Cash Items | 44.83% | 42.01% | 14.93% | -12.34% | -16.84% |
| Change in Net Operating Assets | -445.21% | 709.44% | -447.14% | -37.36% | -99.24% |
| Cash from Operations | -39.14% | -36.06% | -59.08% | -45.62% | -282.66% |
| Capital Expenditure | -143.75% | -15.51% | -38.10% | -20.84% | 18.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 103.95% | 380.04% | 157.44% | -24.43% | -1,076.72% |
| Cash from Investing | 100.25% | 336.54% | 154.55% | -28.10% | -879.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 17.70% | -97.48% | -100.00% | -9.30% | 2,864,485.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 17.70% | -97.48% | -100.00% | -9.30% | 2,864,485.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,438.59% | 67.57% | -87.54% | -607.96% | -11.12% |